Home » Stocks » Erytech Pharma

Erytech Pharma S.A. (ERYP)

Stock Price: $6.03 USD -0.41 (-6.37%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 114.53M
Revenue (ttm) 5.94M
Net Income (ttm) -62.66M
Shares Out 18.99M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $6.03
Previous Close $6.44
Change ($) -0.41
Change (%) -6.37%
Day's Open 6.38
Day's Range 6.03 - 6.38
Day's Volume 2,114
52-Week Range 5.52 - 13.95

More Stats

Market Cap 114.53M
Enterprise Value 48.13M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 18.99M
Float 18.34M
EPS (basic) n/a
EPS (diluted) -2.79
FCF / Share -3.97
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1,805
Short Ratio 0.55
Short % of Float 0.01%
Beta 1.46
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19.29
PB Ratio 1.98
Revenue 5.94M
Operating Income -71.99M
Net Income -62.66M
Free Cash Flow -71.27M
Net Cash 66.39M
Net Cash / Share 3.49
Gross Margin 100.00%
Operating Margin -1,212.83%
Profit Margin -1,186.00%
FCF Margin -1,200.59%
ROA -36.86%
ROE -81.29%
ROIC -234.00%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(266.83% upside)
Current: $6.03
Target: 22.12
*Average 12-month USD price target from 4 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth18.8%32.19%-18.7%41.28%-
Gross Profit5.284.453.364.142.93
Operating Income-64.07-43.62-30.89-22.39-15.58
Net Income-62.66-38.22-33.53-21.91-15.01
Shares Outstanding17.9417.9417.0617.06-
Earnings Per Share-3.49-2.13-2.95-2.74-2.16
Operating Cash Flow-43.31-47.86-24.70-17.61-14.58
Capital Expenditures-20.12-5.64-1.66-1.75-0.27
Free Cash Flow-63.43-53.49-26.37-19.37-14.85
Cash & Equivalents73.2113418637.6545.63
Total Debt14.122.022.842.870.71
Net Cash / Debt59.0913218334.7844.93
Book Value85.5614618135.6447.13
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Erytech Pharma S.A.
Country France
Employees 206
CEO Gil Beyen

Stock Information

Ticker Symbol ERYP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ERYP


ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.